<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39349924</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>01</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>03</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>30</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Systemic cytokines related to memory function 6-9&#xa0;months and 12-15&#xa0;months after SARS-CoV-2 infection.</ArticleTitle><Pagination><StartPage>22660</StartPage><MedlinePgn>22660</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">22660</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-024-72421-z</ELocationID><Abstract><AbstractText>Cognitive symptoms persisting beyond the acute phase of COVID-19 infection are commonly described for up to 2&#xa0;years after infection. The relationship between cognitive performance, in particular episodic memory processes observed chronically after infection, and cytokine levels in the acute phase of COVID-19 has not yet been identified in humans. To determine whether the levels of cytokines IL1&#x3b2;, IL-6 and TNF&#x3b1; secreted in the acute phase of SARS-CoV-2 infection are associated and predict verbal and visuospatial episodic memory performance in humans 6 to 9&#xa0;months and 12 to 15&#xa0;months post-infection. The associations and predictive value of the concentration of cytokines measured in acute phase (IL-1&#x3b2;, IL-6, TNF&#x3b1;) from plasma samples of N&#x2009;=&#x2009;33 hospitalized COVID-19 patients (mean age 61&#xa0;years, 39-78, 65% in intensive care) in relation to their verbal and visuospatial episodic memory performance measured at 6-9&#xa0;months and 12-15&#xa0;months post-infection were analyzed. To do this, we used Spearman correlations and generalised linear mixed models. IL-1&#x3b2; levels were associated with verbal episodic memory total recall scores 6-9&#xa0;months post-infection. At 12-15&#xa0;months post-infection IL-6 predicted verbal episodic memory score. This study demonstrated that the severity of inflammatory reaction at acute phase of SARS-CoV-2 infection predicts verbal episodic memory performance in the long-term post-infection.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nuber-Champier</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Clinical and Experimental Neuropsychology Laboratory, Facult&#xe9; de Psychologie et Des Sciences de l'Education, University of Geneva, 40 bd du Pont d'Arve, 1205, Geneva, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurology Division, Geneva University Hospitals, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Breville</LastName><ForeName>G</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Neurology Division, Geneva University Hospitals, Geneva, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Voruz</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Clinical and Experimental Neuropsychology Laboratory, Facult&#xe9; de Psychologie et Des Sciences de l'Education, University of Geneva, 40 bd du Pont d'Arve, 1205, Geneva, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurosurgery Department, Geneva University Hospitals, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jacot de Alc&#xe2;ntara</LastName><ForeName>I</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Clinical and Experimental Neuropsychology Laboratory, Facult&#xe9; de Psychologie et Des Sciences de l'Education, University of Geneva, 40 bd du Pont d'Arve, 1205, Geneva, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurology Division, Geneva University Hospitals, Geneva, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine, University of Geneva, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cionca</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Clinical and Experimental Neuropsychology Laboratory, Facult&#xe9; de Psychologie et Des Sciences de l'Education, University of Geneva, 40 bd du Pont d'Arve, 1205, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Allali</LastName><ForeName>G</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Leenaards Memory Center, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lalive</LastName><ForeName>P H</ForeName><Initials>PH</Initials><AffiliationInfo><Affiliation>Neurology Division, Geneva University Hospitals, Geneva, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine, University of Geneva, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benzakour</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, University of Geneva, Geneva, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Psychiatry Department, Geneva University Hospitals, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>L&#xf6;vblad</LastName><ForeName>K-O</ForeName><Initials>KO</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, University of Geneva, Geneva, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Diagnostic and Interventional Neuroradiology Department, Geneva University Hospitals, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Braillard</LastName><ForeName>O</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Division and Department of Primary Care, Geneva University Hospitals, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nehme</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division and Department of Primary Care, Geneva University Hospitals, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coen</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of General Internal Medicine, Department of Medicine, Geneva University Hospitals and Geneva University, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Serratrice</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of General Internal Medicine, Department of Medicine, Geneva University Hospitals and Geneva University, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reny</LastName><ForeName>J-L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Division of General Internal Medicine, Department of Medicine, Geneva University Hospitals and Geneva University, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pugin</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, University of Geneva, Geneva, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Intensive Care Department, Geneva University Hospitals, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guessous</LastName><ForeName>I</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, University of Geneva, Geneva, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division and Department of Primary Care, Geneva University Hospitals, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Landis</LastName><ForeName>B N</ForeName><Initials>BN</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, University of Geneva, Geneva, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Rhinology-Olfactology Unit, Otorhinolaryngology Department, Geneva University Hospitals, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Assal</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Neurology Division, Geneva University Hospitals, Geneva, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine, University of Geneva, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>P&#xe9;ron</LastName><ForeName>Julie Anne</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Clinical and Experimental Neuropsychology Laboratory, Facult&#xe9; de Psychologie et Des Sciences de l'Education, University of Geneva, 40 bd du Pont d'Arve, 1205, Geneva, Switzerland. julie.peron@unige.ch.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurology Division, Geneva University Hospitals, Geneva, Switzerland. julie.peron@unige.ch.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>220041</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>220041</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053583">Interleukin-1beta</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="Y">Cytokines</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053583" MajorTopicYN="Y">Interleukin-1beta</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061212" MajorTopicYN="N">Memory, Episodic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Cognition</Keyword><Keyword MajorTopicYN="N">Immunity</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">Memory</Keyword><Keyword MajorTopicYN="N">Post-COVID</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>1</Day><Hour>10</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>30</Day><Hour>23</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39349924</ArticleId><ArticleId IdType="pmc">PMC11443073</ArticleId><ArticleId IdType="doi">10.1038/s41598-024-72421-z</ArticleId><ArticleId IdType="pii">10.1038/s41598-024-72421-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Davis, H. E., McCorkell, L., Vogel, J. M. &amp; Topol, E. J. Long COVID: Major findings, mechanisms and recommendations. Nat. Rev. Microbiol.1, 1&#x2013;14 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomasson, M. et al. Markers of limbic system damage following SARS-CoV-2 infection. Brain Commun.5, fcad177 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10320753</ArticleId><ArticleId IdType="pubmed">37415776</ArticleId></ArticleIdList></Reference><Reference><Citation>Voruz, P. et al. Frequency of abnormally low neuropsychological scores in post-COVID-19 syndrome: the Geneva COVID-COG cohort. Arch. Clin. Neuropsychol. (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9384624</ArticleId><ArticleId IdType="pubmed">35942646</ArticleId></ArticleIdList></Reference><Reference><Citation>Soriano, J. B., Murthy, S., Marshall, J. C., Relan, P. &amp; Diaz, J. V. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet. Infect. Dis22, e102&#x2013;e107 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8691845</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>Ceban, F. et al. Fatigue and cognitive impairment in Post-COVID-19 Syndrome: A systematic review and meta-analysis. Brain Behav. Immun.101, 93&#x2013;135 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8715665</ArticleId><ArticleId IdType="pubmed">34973396</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet, M. et al. Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: An analysis of 2-year retrospective cohort studies including 1 284 437 patients. Lancet Psychiatry9, 815&#x2013;827 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9385200</ArticleId><ArticleId IdType="pubmed">35987197</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#xed;ez-Cirarda, M. et al. Multimodal neuroimaging in post-COVID syndrome and correlation with cognition. Brain146, 2142&#x2013;2152 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9620345</ArticleId><ArticleId IdType="pubmed">36288544</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartung, T. J. et al. Fatigue and cognitive impairment after COVID-19: A prospective multicentre study. EClinicalMedicine53 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9482331</ArticleId><ArticleId IdType="pubmed">36133318</ArticleId></ArticleIdList></Reference><Reference><Citation>Voruz, P. et al. Long COVID neuropsychological deficits after severe, moderate, or mild infection. Clin. Transl. Neurosci.6, 9 (2022).</Citation></Reference><Reference><Citation>Morioka, S. et al. Epidemiology of post-COVID conditions beyond 1 year: A cross-sectional study. Public Health216, 39&#x2013;44 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36791649</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis, H. E. et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine38 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8280690</ArticleId><ArticleId IdType="pubmed">34308300</ArticleId></ArticleIdList></Reference><Reference><Citation>Monje, M. &amp; Iwasaki, A. The neurobiology of long COVID. Neuron (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9537254</ArticleId><ArticleId IdType="pubmed">36288726</ArticleId></ArticleIdList></Reference><Reference><Citation>Greene, C. et al. Blood&#x2013;brain barrier disruption and sustained systemic inflammation in individuals with long COVID-associated cognitive impairment. Nat. Neurosci.27, 421&#x2013;432 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10917679</ArticleId><ArticleId IdType="pubmed">38388736</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein, J. et al. Distinguishing features of Long COVID identified through immune profiling. Nature 1&#x2013;3 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10620090</ArticleId><ArticleId IdType="pubmed">37748514</ArticleId></ArticleIdList></Reference><Reference><Citation>Nuber-Champier, A. et al. Monocytosis in the acute phase of SARS-CoV-2 infection predicts the presence of anosognosia for cognitive deficits in the chronic phase. Brain Behav. Immun. Health26, 100511 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9477785</ArticleId><ArticleId IdType="pubmed">36128057</ArticleId></ArticleIdList></Reference><Reference><Citation>Etter, M. M. et al. Severe Neuro-COVID is associated with peripheral immune signatures, autoimmunity and neurodegeneration: A prospective cross-sectional study. Nat. Commun.13, 6777 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9645766</ArticleId><ArticleId IdType="pubmed">36351919</ArticleId></ArticleIdList></Reference><Reference><Citation>Soung, A. L. et al. COVID-19 induces CNS cytokine expression and loss of hippocampal neurogenesis. Brain145, 4193&#x2013;4201 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9452175</ArticleId><ArticleId IdType="pubmed">36004663</ArticleId></ArticleIdList></Reference><Reference><Citation>McAfoose, J. &amp; Baune, B. Evidence for a cytokine model of cognitive function. Neurosci. Biobehav. Rev.33, 355&#x2013;366 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">18996146</ArticleId></ArticleIdList></Reference><Reference><Citation>Nuber-Champier, A. et al. Acute TNF&#x3b1; levels predict cognitive impairment 6&#x2013;9 months after COVID-19 infection. Psychoneuroendocrinology 106104 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10066791</ArticleId><ArticleId IdType="pubmed">37104966</ArticleId></ArticleIdList></Reference><Reference><Citation>Voruz, P. et al. Functional connectivity underlying cognitive and psychiatric symptoms in post-COVID-19 syndrome: Is anosognosia a key determinant? Brain Commun. 4, fcac057 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8956133</ArticleId><ArticleId IdType="pubmed">35350554</ArticleId></ArticleIdList></Reference><Reference><Citation>Zorzo, C., Solares, L., Mendez, M. &amp; Mendez-Lopez, M. Hippocampal alterations after SARS-CoV-2 infection: A systematic review. Behav. Brain Res. 114662 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37703951</ArticleId></ArticleIdList></Reference><Reference><Citation>Voruz, P. et al. Brain functional connectivity alterations associated with neuropsychological performance 6&#x2013;9 months following SARS-CoV-2 infection. Hum. Brain Mapp.1, 1 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9878070</ArticleId><ArticleId IdType="pubmed">36458984</ArticleId></ArticleIdList></Reference><Reference><Citation>Toniolo, S., Di Lorenzo, F., Scarioni, M., Frederiksen, K. S. &amp; Nobili, F. Is the frontal lobe the primary target of SARS-CoV-2?. J. Alzheimer&#x2019;s Dis.81, 75&#x2013;81 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33720900</ArticleId></ArticleIdList></Reference><Reference><Citation>Douaud, G. et al. SARS-CoV-2 is associated with changes in brain structure in UK Biobank. Nature604, 697&#x2013;707 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9046077</ArticleId><ArticleId IdType="pubmed">35255491</ArticleId></ArticleIdList></Reference><Reference><Citation>Hosp, J. A. et al. Cognitive impairment and altered cerebral glucose metabolism in the subacute stage of COVID-19. Brain144, 1263&#x2013;1276 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8083602</ArticleId><ArticleId IdType="pubmed">33822001</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarifkar, P., Peinkhofer, C., Benros, M. E. &amp; Kondziella, D. Frequency of neurological diseases after COVID-19, influenza A/B and bacterial pneumonia. Front. Neurol.13, 1276 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9259944</ArticleId><ArticleId IdType="pubmed">35812108</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine, K. S. et al. Virus exposure and neurodegenerative disease risk across national biobanks. Neuron1, 1 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10079561</ArticleId><ArticleId IdType="pubmed">36669485</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva, N. M. L., Barros-Arag&#xe3;o, F. G., De Felice, F. G. &amp; Ferreira, S. T. Inflammation at the crossroads of COVID-19, cognitive deficits and depression. Neuropharmacology209, 109023 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8894741</ArticleId><ArticleId IdType="pubmed">35257690</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartz, M. &amp; Cahalon, L. The vicious cycle governing the brain&#x2013;immune system relationship in neurodegenerative diseases. Curr. Opin. Immunol.76, 102182 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35576769</ArticleId></ArticleIdList></Reference><Reference><Citation>Dursun, E. et al. The interleukin 1 alpha, interleukin 1 beta, interleukin 6 and alpha-2-macroglobulin serum levels in patients with early or late onset Alzheimer&#x2019;s disease, mild cognitive impairment or Parkinson&#x2019;s disease. J. Neuroimmunol.283, 50&#x2013;57 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26004156</ArticleId></ArticleIdList></Reference><Reference><Citation>Trapero, I. &amp; Cauli, O. Interleukin 6 and cognitive dysfunction. Metab. Brain Dis.29, 593&#x2013;608 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24782046</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet, M. et al. Acute blood biomarker profiles predict cognitive deficits 6 and 12 months after COVID-19 hospitalization. Nat. Med.1, 1&#x2013;11 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10579097</ArticleId><ArticleId IdType="pubmed">37653345</ArticleId></ArticleIdList></Reference><Reference><Citation>Damiano, R. F. et al. Cognitive impairment in long-COVID and its association with persistent dysregulation in inflammatory markers. Front. Immunol.14, 1174020 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10242059</ArticleId><ArticleId IdType="pubmed">37287969</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeidman, P. &amp; Maguire, E. A. Anterior hippocampus: The anatomy of perception, imagination and episodic memory. Nat. Rev. Neurosci.17, 173&#x2013;182 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5358751</ArticleId><ArticleId IdType="pubmed">26865022</ArticleId></ArticleIdList></Reference><Reference><Citation>Altmann, D. M., Whettlock, E. M., Liu, S., Arachchillage, D. J. &amp; Boyton, R. J. The immunology of long COVID. Nat. Rev. Immunol.23, 618&#x2013;634 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37433988</ArticleId></ArticleIdList></Reference><Reference><Citation>Nottet, H. S. &amp; Gendelman, H. E. Unraveling the neuroimmune mechanisms for the HIV-1-associated cognitive/motor complex. Immunology today16, 441&#x2013;448 (1995).</Citation><ArticleIdList><ArticleId IdType="pubmed">7546209</ArticleId></ArticleIdList></Reference><Reference><Citation>Maier, S. F. &amp; Watkins, L. R. Cytokines for psychologists: Implications of bidirectional immune-to-brain communication for understanding behavior, mood, and cognition. Psychol. Rev.105, 83 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9450372</ArticleId></ArticleIdList></Reference><Reference><Citation>Magaki, S., Mueller, C., Dickson, C. &amp; Kirsch, W. Increased production of inflammatory cytokines in mild cognitive impairment. Exp. Gerontol.42, 233&#x2013;240 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1868444</ArticleId><ArticleId IdType="pubmed">17085001</ArticleId></ArticleIdList></Reference><Reference><Citation>Frontera, J. A. et al. Trajectories of inflammatory markers and post-COVID-19 cognitive symptoms: A secondary analysis of the CONTAIN COVID-19 randomized trial. Neurol. Neuroimmunol. Neuroinflamm.11, e200227 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11087048</ArticleId><ArticleId IdType="pubmed">38626359</ArticleId></ArticleIdList></Reference><Reference><Citation>Bermejo, P. et al. Differences of peripheral inflammatory markers between mild cognitive impairment and Alzheimer&#x2019;s disease. Immunol. Lett.117, 198&#x2013;202 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18367253</ArticleId></ArticleIdList></Reference><Reference><Citation>Eustache, F., Viard, A. &amp; Desgranges, B. The MNESIS model: Memory systems and processes, identity and future thinking. Neuropsychologia87, 96&#x2013;109 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27178309</ArticleId></ArticleIdList></Reference><Reference><Citation>Grober, E. &amp; Buschke, H. Genuine memory deficits in dementia. Dev. Neuropsychol.3, 13&#x2013;36 (1987).</Citation></Reference><Reference><Citation>Meyers, J. E. &amp; Meyers, K. R. Rey Complex Figure Test and recognition trial professional manual. (Psychological Assessment Resources, 1995).</Citation></Reference><Reference><Citation>Nuber-Champier, A. et al. Monocytosis in the acute phase of SARS-CoV-2 infection predicts the presence of anosognosia for cognitive deficits in the chronic phase. Brain Behav. Immunity Health26, 1. 10.1016/j.bbih.2022.100511 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9477785</ArticleId><ArticleId IdType="pubmed">36128057</ArticleId></ArticleIdList></Reference><Reference><Citation>Sb, C. H., Browner, W., Grady, D., Newman, T. &amp; Gaertner, R. Designing clinical research: An epidemiologic approach (2013).</Citation></Reference><Reference><Citation>Genser, B., Cooper, P. J., Yazdanbakhsh, M., Barreto, M. L. &amp; Rodrigues, L. C. A guide to modern statistical analysis of immunological data. BMC Immunol.8, 1&#x2013;15 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2234437</ArticleId><ArticleId IdType="pubmed">17963513</ArticleId></ArticleIdList></Reference><Reference><Citation>De Winter, J. C., Gosling, S. D. &amp; Potter, J. Comparing the Pearson and Spearman correlation coefficients across distributions and sample sizes: A tutorial using simulations and empirical data. Psychol. Methods21, 273 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27213982</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>